These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 23429371)

  • 21. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.
    Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K
    Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical, radiological and molecular characterization of intramedullary astrocytomas.
    Lebrun L; Meléndez B; Blanchard O; De Nève N; Van Campenhout C; Lelotte J; Balériaux D; Riva M; Brotchi J; Bruneau M; De Witte O; Decaestecker C; D'Haene N; Salmon I
    Acta Neuropathol Commun; 2020 Aug; 8(1):128. PubMed ID: 32771057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
    Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
    Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
    Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.
    Rorive S; Maris C; Debeir O; Sandras F; Vidaud M; Bièche I; Salmon I; Decaestecker C
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):794-807. PubMed ID: 16896313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
    Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?
    Gessi M; Gielen GH; Hammes J; Dörner E; Mühlen AZ; Waha A; Pietsch T
    J Neurooncol; 2013 Mar; 112(1):67-72. PubMed ID: 23354654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
    Kleinschmidt-DeMasters BK; Mulcahy Levy JM
    Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
    Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM
    Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
    Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas.
    Bechet D; Gielen GG; Korshunov A; Pfister SM; Rousso C; Faury D; Fiset PO; Benlimane N; Lewis PW; Lu C; David Allis C; Kieran MW; Ligon KL; Pietsch T; Ellezam B; Albrecht S; Jabado N
    Acta Neuropathol; 2014 Nov; 128(5):733-41. PubMed ID: 25200321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
    Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours.
    Nguyen AT; Colin C; Nanni-Metellus I; Padovani L; Maurage CA; Varlet P; Miquel C; Uro-Coste E; Godfraind C; Lechapt-Zalcman E; Labrousse F; Gauchotte G; Silva K; Jouvet A; Figarella-Branger D;
    Neuropathol Appl Neurobiol; 2015 Apr; 41(3):403-8. PubMed ID: 25389051
    [No Abstract]   [Full Text] [Related]  

  • 40. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
    Feng J; Hao S; Pan C; Wang Y; Wu Z; Zhang J; Yan H; Zhang L; Wan H
    Hum Pathol; 2015 Nov; 46(11):1626-32. PubMed ID: 26297251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.